ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE
    14.
    发明申请
    ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE 审中-公开
    IL-12,IL-23和IL-17受体在炎症性皮肤疾病中的作用

    公开(公告)号:US20100055700A1

    公开(公告)日:2010-03-04

    申请号:US12528668

    申请日:2008-02-28

    IPC分类号: C12Q1/68

    摘要: This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors.

    摘要翻译: 本发明通过确定IL-12,IL-23和/或IL-17受体基因中遗传变体的存在或不存在来提供诊断或预测个体易感性或保护免疫性肠病的方法。 在一个实施方案中,通过测定IL-12,IL-23和/或IL-17受体的风险和/或保护性单倍型的存在或不存在来实施本发明的方法。

    Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease
    16.
    发明授权
    Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease 有权
    用于诊断和治疗克罗恩病的CBir1抗原应答的表征

    公开(公告)号:US08153443B2

    公开(公告)日:2012-04-10

    申请号:US12599549

    申请日:2008-05-09

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。

    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
    17.
    发明申请
    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 有权
    CBIR1抗原反应诊断和治疗高血糖病的特征

    公开(公告)号:US20100284999A1

    公开(公告)日:2010-11-11

    申请号:US12599549

    申请日:2008-05-09

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。

    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
    18.
    发明申请
    CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 审中-公开
    CBIR1抗原反应诊断和治疗高血糖病的特征

    公开(公告)号:US20130058953A1

    公开(公告)日:2013-03-07

    申请号:US13410881

    申请日:2012-03-02

    摘要: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.

    摘要翻译: 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中,本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中,本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中,本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。

    METHODS OF DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE
    20.
    发明申请
    METHODS OF DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 审中-公开
    诊断和治疗冠心病的方法

    公开(公告)号:US20100144903A1

    公开(公告)日:2010-06-10

    申请号:US12598794

    申请日:2008-05-02

    IPC分类号: A61K31/00 C12Q1/68 A61P1/00

    摘要: In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus.

    摘要翻译: 在一个实施方案中,本发明通过确定IL23R,IL17A,IL17RA和/或IL12RB1基因座中风险单倍体的存在或不存在来提供诊断和/或预测克罗恩病易感性的方法。 在另一个实施方案中,本发明提供了通过确定在IL12RB2基因座处存在或不存在风险单倍型来诊断和/或预测个体中克罗恩病易感性的方法。